Rabeprazole Suppressed Gastric Intestinal Metaplasia Through Activation of GPX4-mediated Ferroptosis

Overview

Journal Front Pharmacol

Date 2024 Nov 22

PMID 39575386

Authors

Jing Xie

Xinhua Liang

Fangfang Xie

Canxin Huang

Zijun Lin

Shuping Xie

Fangying Yang

Fengfeng Zheng

Lanlan Geng

Wanfu Xu

Sitang Gong

Li Xiang

Affiliations

Soon will be listed here.

Abstract

Background: Gastric intestinal metaplasia is a common pathological feature in patients with () infection. Rabeprazole was widely used as the first-line regimen for infectious treatment. The objective of this study is to explore the mechanism of rabeprazole in gastric intestinal metaplasia treatment.

Methods: Real-time PCR, Western blotting (WB) and ROS analysis were conducted to confirm that rabeprazole could induce ferroptosis to suppress gastric intestinal metaplasia. Cellular fraction, luciferase and chromatin immunoprecipitation (ChIP) were used to identify the mechanism underlying rabeprazole modulated ferroptosis.

Results: Herein, we found rabeprazole treatment led to inhibit CDX2 and MUC2 expression, alleviating gastric intestinal metaplasia, which was attributed to enhanced ferroptosis characterized by decreased GPX4 expression. Inhibition of ferroptosis by ferrostatin-1 (Fer-1) could reverse decreased CDX2 and MUC2 expression caused by rabeprazole. Mechanically, Rabeprazole could inhibit CREB phosphorylation and nuclear translocation, which further decreased the binding of CREB to GPX4 promoter, reducing GPX4 transactivity. Moreover, endogenous PKA interacted with CREB, and this interaction was drastically destroyed in response to rabeprazole treatment. Most importantly, enhanced ferroptosis was observed in infected gastric intestinal metaplasia in comparison to HC control.

Conclusion: These findings suggested that rabeprazole induced ferroptosis to reduce CDX2 expression in gastric epithelial cells through PKA/CREB cascade signaling, implying that targeting ferroptosis could be a promising strategy in improving gastric intestinal metaplasia during -infected patients.

References

Wang Y, Zhou X, Zou K, Chen G, Huang L, Yang F . Monocarboxylate Transporter 4 Triggered Cell Pyroptosis to Aggravate Intestinal Inflammation in Inflammatory Bowel Disease. Front Immunol. 2021; 12:644862. PMC: 8170300. DOI: 10.3389/fimmu.2021.644862. View

Pai Y, Li Y, Turner J, Yu L . Transepithelial Barrier Dysfunction Drives Microbiota Dysbiosis to Initiate Epithelial Clock-driven Inflammation. J Crohns Colitis. 2023; 17(9):1471-1488. PMC: 10588795. DOI: 10.1093/ecco-jcc/jjad064. View

Li M, Zhao J, Cao M, Liu R, Chen G, Li S . Mast cells-derived MiR-223 destroys intestinal barrier function by inhibition of CLDN8 expression in intestinal epithelial cells. Biol Res. 2020; 53(1):12. PMC: 7092522. DOI: 10.1186/s40659-020-00279-2. View

Lv Y, Chen D, Tian X, Xiao J, Xu C, Du L . Protectin conjugates in tissue regeneration 1 alleviates sepsis-induced acute lung injury by inhibiting ferroptosis. J Transl Med. 2023; 21(1):293. PMC: 10150510. DOI: 10.1186/s12967-023-04111-9. View

Song B, Li T, Zhang Y, Yang Q, Pei B, Liu Y . Identification and verification of ferroptosis-related genes in gastric intestinal metaplasia. Front Genet. 2023; 14:1152414. PMC: 10151495. DOI: 10.3389/fgene.2023.1152414. View

Xu W, Zhang Z, Zou K, Cheng Y, Yang M, Chen H . MiR-1 suppresses tumor cell proliferation in colorectal cancer by inhibition of Smad3-mediated tumor glycolysis. Cell Death Dis. 2017; 8(5):e2761. PMC: 5520746. DOI: 10.1038/cddis.2017.60. View

Du B, Luo M, Ren C, Zhang J . PDE4 inhibitors for disease therapy: advances and future perspective. Future Med Chem. 2023; 15(13):1185-1207. DOI: 10.4155/fmc-2023-0101. View

McDonough W, Aragon I, Rich J, Murphy J, Abou Saleh L, Boyd A . PAN-selective inhibition of cAMP-phosphodiesterase 4 (PDE4) induces gastroparesis in mice. FASEB J. 2020; 34(9):12533-12548. PMC: 7954513. DOI: 10.1096/fj.202001016RR. View

Lv F, Wang J, Mao L, Zhou X, Zhang T, Zhou S . Whether long-term use of proton pump inhibitor increases the risk of precancerous lesions in the stomach: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2023; 102(38):e35062. PMC: 10519510. DOI: 10.1097/MD.0000000000035062. View

10.

Zhao L, Peng Y, He S, Li R, Wang Z, Huang J . Apatinib induced ferroptosis by lipid peroxidation in gastric cancer. Gastric Cancer. 2021; 24(3):642-654. DOI: 10.1007/s10120-021-01159-8. View

11.

Okuda S, Honda M, Ito Y, Aihara E, Kato S, Mitsufuji S . Phosphodiesterase isozymes involved in regulating acid secretion in the isolated mouse stomach. J Physiol Pharmacol. 2010; 60 Suppl 7:183-90. View

12.

Liang X, Du W, Huang L, Xiang L, Pan W, Yang F . Helicobacter pylori promotes gastric intestinal metaplasia through activation of IRF3-mediated kynurenine pathway. Cell Commun Signal. 2023; 21(1):141. PMC: 10273570. DOI: 10.1186/s12964-023-01162-9. View

13.

Crocetti L, Floresta G, Cilibrizzi A, Giovannoni M . An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022. Molecules. 2022; 27(15). PMC: 9370432. DOI: 10.3390/molecules27154964. View

14.

Zhang H, Deng T, Liu R, Ning T, Yang H, Liu D . CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer. 2020; 19(1):43. PMC: 7045485. DOI: 10.1186/s12943-020-01168-8. View

15.

Zhu W, Liu D, Lu Y, Sun J, Zhu J, Xing Y . PHKG2 regulates RSL3-induced ferroptosis in Helicobacter pylori related gastric cancer. Arch Biochem Biophys. 2023; 740:109560. DOI: 10.1016/j.abb.2023.109560. View

16.

Wang C, Chu Q, Dong W, Wang X, Zhao W, Dai X . Microbial metabolite deoxycholic acid-mediated ferroptosis exacerbates high-fat diet-induced colonic inflammation. Mol Metab. 2024; 84:101944. PMC: 11070703. DOI: 10.1016/j.molmet.2024.101944. View

17.

Ni H, Qin H, Sun C, Liu Y, Ruan G, Guo Q . MiR-375 reduces the stemness of gastric cancer cells through triggering ferroptosis. Stem Cell Res Ther. 2021; 12(1):325. PMC: 8180146. DOI: 10.1186/s13287-021-02394-7. View

18.

Du K, Wang L, Jun J, Dutta R, Maeso-Diaz R, Oh S . Aging promotes metabolic dysfunction-associated steatotic liver disease by inducing ferroptotic stress. Nat Aging. 2024; 4(7):949-968. DOI: 10.1038/s43587-024-00652-w. View

19.

Ichikawa H, Yoshida N, Takagi T, Tomatsuri N, Katada K, Isozaki Y . Lansoprazole ameliorates intestinal mucosal damage induced by ischemia-reperfusion in rats. World J Gastroenterol. 2004; 10(19):2814-7. PMC: 4572108. DOI: 10.3748/wjg.v10.i19.2814. View

20.

Chen H, Hu Y, Xu X, Zhou Y, Li N, He C . Upregulation of oncogene Activin A receptor type I by Helicobacter pylori infection promotes gastric intestinal metaplasia via regulating CDX2. Helicobacter. 2021; 26(6):e12849. DOI: 10.1111/hel.12849. View